GO
| HSI1 | 24,498.95 | -18.81 | 236.41B |
| HSCEI1 | 8,853.10 | -8.29 | 74.68B |
| Back Zoom + Zoom - Block Traded | |
|
2025-07-17 11:45:55 SINO BIOPHARM (01177.HK) recently acquired 95.09% equity in LaNova Medicines for USD950.92 million, CICC published a research report saying. After deducting approximately USD450 million in cash and deposits held by LaNova Medicines, the net consideration amounted to USD500 million. Upon completion of the acquisition, LaNova Medicines will become a wholly-owned subsidiary of SINO BIOPHARM. LaNova Medicines possesses global innovation capabilities verified by MNC, with adequate first-in-class (FIC)/best-in-class (BIC) pipelines, CICC added. This acquisition is expected to empower SINO BIOPHARM to open a new chapter in its innovative drug business. Considering the upside in sector valuation pivot, CICC raised its target price for the stock by 26.7% to $7.6, corresponding to 2025/ 2026 PE ratios of 34.6x/ 31.1x each, implying a 19.3% upside potential compared to the closing price of $6.37 on Tuesday (15 July), with rating kept at Outperform. ~ AASTOCKS Financial News Website: www.aastocks.com | |